Streetbeat News

FLHLF

Filament Health Corp

Open

0.02

Mkt cap

4.1M

Volume

27K

High

0.02

P/E Ratio

-1.55

52-wk high

0.06

Low

0.01

Div yield

N/A

52-wk low

0.01

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

The article provides a comprehensive roundup of recent developments in the psychedelics sector, highlighting research findings, regulatory updates, and industry movements. Key highlights include the launch of Usona Institute's Phase 3 clinical trial on psilocybin for Major Depressive Disorder, partnerships for psilocybin research, and significant corporate changes within companies like Compass Pathways and Cybin. Additionally, several companies announced progress in clinical trials, patent approvals, and expansions in product distribution.

Portfolio Pulse from Lara Goldstein

March 30, 2024 | 12:57 pm

President Biden signed the 2024 NDAA, which includes funding for clinical trials with psychedelics for active military members. Robert F. Kennedy Jr. expressed support for psychedelics in mental health treatment. Incannex Healthcare (NASDAQ:IXHL) is set to open Australia's first dedicated psychedelic-assisted therapy clinic. Psychedelics stocks showed varied performance, with COMPASS Pathways (NASDAQ:CMPS) closing at $8.75, and AdvisorShares Psychedelics ETF (NYSE:PSIL) closing at $1.42.

Portfolio Pulse from Lara Goldstein

December 27, 2023 | 3:09 pm

Billionaire Steve Cohen has invested nearly $19 million in Cybin Inc. (NYSE:CYBN) for psychedelics R&D. A new bill in Congress aims to discourage federal intervention in states that legalize or decriminalize psilocybin mushrooms. Enthea, a healthcare benefits administrator, is expanding its network to include psychedelic-assisted therapies in health benefit plans. Magdalena Biosciences, Jaguar Health (NASDAQ:JAGX) and Filament Health (OTC:FLHLF) are developing plant-based medicines for mental health indications. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.70 on Sept. 18, slightly below previous openings.

Portfolio Pulse from Lara Goldstein

September 26, 2023 | 1:28 pm

Magdalena Biosciences, Jaguar Health (NASDAQ:JAGX) and Filament Health (OTCQB:FLHLF) have formed a joint venture to develop plant-based medicines for mental health indications. They have imported Peruvian coca leaf to Canada for research into potential treatments for adult ADHD. The coca leaves were authorized for import by the Peruvian Health Authority and will be used in Filament’s facility, Psilo Scientific, for initial research purposes.

Portfolio Pulse from Lara Goldstein

September 21, 2023 | 8:46 pm

Filament Health Corp. and Jaguar Health, Inc. have successfully completed an import of coca leaf to Filament's Metro Vancouver research and development facility. The import was authorized by the Peruvian Health Authority and acquired from the Empresa Nacional de la Coca. The imported leaves will be used for initial research purposes to look at neuropsychiatric indications.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:33 am

Imperial College London's Centre for Psychedelic Research will begin a government-funded study in October to assess psilocybin-assisted therapy for gambling addiction. The University of Calgary will also launch a clinical trial in October to study the effects of psilocybin paired with Motivational Enhancement Therapy on heavy drinking in patients with Alcohol Use Disorder. In January 2024, a Phase 2 clinical trial will begin to assess the feasibility, safety, and preliminary efficacy of one psilocybin dose to alleviate opioid-refractory pain in advanced cancer patients. This trial will use Filament Health's (OTC:FLHLF) natural psilocybin and is funded by Cy Biopharma and Pancreatic Cancer North America.

Portfolio Pulse from Lara Goldstein

August 24, 2023 | 12:09 am

A recent study by the Federal Reserve indicates that cannabis and psychedelics consumption has reached all-time highs in 2022, particularly among adults aged 35-50. In other news, COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and a potential additional $160 million, while MindMed (NASDAQ:MNMD) has secured a $50 million senior secured credit facility with K2 HealthVentures. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.8 on August 14, slightly below prior openings.

Portfolio Pulse from Lara Goldstein

August 21, 2023 | 2:55 pm

Filament Health (OTCQB:FLHLF) has released its Q1 2023 financial results, showing a decrease in total cash and an accumulated deficit of $19.6 million. The company has expressed uncertainties about its ability to execute its business plan and continue operations without additional financing. Filament has announced its intention to list on the NASDAQ through a business combination with Jupiter Acquisition Corp. (NASDAQ:JAQC). The company has also reported progress in its drug development program, including FDA approval of two clinical studies and a global licensing agreement with NeoLumina Bioscience Inc.

Portfolio Pulse from Lara Goldstein

August 15, 2023 | 10:21 pm

Minneapolis Mayor Jacob Frey has signed an executive order deprioritizing criminal prosecution for possession, use, purchase, cultivation and engaging in practices with “entheogenic plants or plant compounds. German company Acid Berlin is selling a reportedly legal LSD prodrug and shipping it through DHL Group to clients based in Berlin. Reunion Neuroscience is on the brink of going private with final court approval. Filament Health gets ready to uplist to NASDAQ in a $210M SPAC deal. Sales of Johnson & Johnson esketamine drug Spravato rose nearly 100% year-over-year. PharmaTher's DMT patch showed positive outcomes, investment toward the clinical stage. Enveric Biosciences unveiled positive results from animal studies of its psilocin prodrug for anxiety. Core One Labs entered a LOI for the first sale of its psychedelic biosynthetic compounds. AdvisorShares Psychedelics ETF opened Monday, July 24, at $1.94, dropping from prior Friday’s closing at $1.99.

Portfolio Pulse from Lara Goldstein

July 24, 2023 | 9:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.